Aim Immunotech Stock Price, News & Analysis

AIM ImmunoTech Inc. announced promising results for Ampligen® (rintatolimod) as a potential maintenance therapy for advanced pancreatic cancer. Following FDA clearance, AIM will commence a Phase 2 study (AMP-270) in Q3 2022, comparing Ampligen to a no-treatment control after FOLFIRINOX chemotherapy. The trial will enroll around 90 patients at multiple sites in the U.S. and Europe. Recent data showed improved median survival times for patients treated with Ampligen compared to historical controls, indicating its potential effectiveness in this challenging indication.

AIM ImmunoTech announced positive results from a Phase 1 study on metastatic triple-negative breast cancer (mTNBC), utilizing chemokine modulation therapy with Ampligen and pembrolizumab. The trial met its primary endpoint by enhancing cytotoxic T-lymphocyte infiltration in the tumor microenvironment. Results indicated significant disease stabilization in three out of six patients and impressive immune marker increases, suggesting potential efficacy. The data was presented at the AACR Annual Meeting 2022.

AIM ImmunoTech Inc. (AIM) announced positive results from its Phase 2a clinical study on Ampligen for treating colorectal cancer metastatic to the liver. The primary endpoint was achieved with a significant increase in CD8a expression post-treatment (p=0.046), suggesting that the CKM regimen may enhance immunotherapy effectiveness. Data presented at the AACR 2022 showed improved ratios of CD8a/CD4 and CD8a/FOXP3, indicating a favorable immune response. The median overall survival was 10.5 months. However, no tumor responses were observed, and adverse events were reported in 74% of participants.

AIM ImmunoTech reported its 2021 financial results, noting significant progress in its oncology pipeline and Ampligen^® data demonstrating efficacy across various cancer treatments. The FDA lifted the clinical hold on Ampligen's Phase 2 study for pancreatic cancer, allowing advanced trials to proceed. AIM has a strong cash position of $48.3 million as of December 31, 2021, and expects to maintain operations and clinical programs through 2023. The company aims to leverage upcoming clinical and regulatory milestones in 2022 to drive further growth.

AIM ImmunoTech announced study data on Ampligen's effects on pancreatic cancer cells, accepted for presentation at the 15th Annual IHPBA World Congress from March 30 to April 2, 2022. The study revealed that Ampligen decreased proliferation and migration in specific pancreatic ductal adenocarcinoma (PDAC) cell lines, showing potential anti-tumor effects. Led by Dr. Hassana El Haddaoui, the findings suggest a promising role for Ampligen in treating pancreatic cancer, emphasizing its interaction with Toll-Like Receptor 3. Further evaluation is planned to assess its therapeutic potential.

AIM ImmunoTech Inc. (NYSE: AIM) announced that research led by Dr. Shipra Gandhi at Roswell Park has been accepted for presentation at the AACR Annual Meeting 2022. The study, titled Negative impact of paclitaxel on human breast tumor microenvironment and its reversal by the combination of interferon-α with TLR3 agonist rintatolimod, will highlight the effects of paclitaxel on chemokine systems in breast tumors. The presentation is scheduled for April 12, 2022. This research suggests that the combination of Ampligen and interferon-α may enhance the efficacy of taxane-based chemotherapy.

AIM ImmunoTech Inc. will participate in the 2022 Virtual Growth Conference, hosted by Maxim Group LLC, from March 28-30, 2022. CEO Thomas Equels is set to join a live panel titled "Pancreatic Cancer: Turning the Tide for One of the Most Challenging Indications in Oncology" on March 28th at 12:00 PM ET. The conference will feature discussions across various sectors, providing a platform for company presentations and live Q&A sessions. Interested participants can sign up for M-Vest membership to attend.

AIM ImmunoTech announced that the FDA has lifted the clinical hold on its Phase 2 study of Ampligen for advanced pancreatic cancer, allowing the trial to proceed. Preliminary data suggests Ampligen may improve survival rates following FOLFIRINOX chemotherapy. The upcoming trial, AMP-270, aims to enroll about 90 subjects across 30 centers in the U.S. and Europe, assessing efficacy and safety compared to a no-treatment control. This milestone enhances the potential treatment landscape for pancreatic cancer, which currently has limited options.

AIM ImmunoTech Inc. has announced the acceptance of data from its ongoing Phase 2 clinical study of Ampligen® (rintatolimod) for treating cisplatin-resistant advanced recurrent ovarian cancer. The data will be presented at the AACR Annual Meeting 2022, scheduled for April 8-13 in New Orleans. This single-arm trial, conducted by the University of Pittsburgh Medical Center, shows promising results with a clinical benefit rate of 61.6% among 13 evaluable patients. The study aims to confirm these findings while enhancing our understanding of the tumor microenvironment.